A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following HSCT
Clinical Trial Grant
Administered By
Pediatrics, Infectious Diseases
Awarded By
Merck Sharp & Dohme
Start Date
October 10, 2018
End Date
October 31, 2023
Administered By
Pediatrics, Infectious Diseases
Awarded By
Merck Sharp & Dohme
Start Date
October 10, 2018
End Date
October 31, 2023